Anthonie J. Van Der Wekken

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 26, 2026

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125].

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125].

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 25, 2026

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

Target Attainment and Clinical and Biochemical Parameters Associated with the Pharmacokinetics of 12 Tyrosine Kinase Inhibitors.

Journal: Clinical pharmacokinetics

Published: February 03, 2026

Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.

Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.

Journal: Applied health economics and health policy

Published: December 08, 2025

Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).

Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 05, 2025

Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports.

Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports.

Journal: Virchows Archiv : an international journal of pathology

Published: August 21, 2025

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.

Journal: Translational oncology

Published: August 15, 2025

Genomic distinctions in adolescent and young adult cancer: A comprehensive review.

Genomic distinctions in adolescent and young adult cancer: A comprehensive review.

Journal: Cancer treatment reviews

Published: July 24, 2025

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.

Journal: Clinical pharmacokinetics

Published: July 14, 2025

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 24, 2025

Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity.

Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity.

Journal: Cancer chemotherapy and pharmacology

Published: June 11, 2025

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Journal: Targeted oncology

Published: May 07, 2025

Showing 1-12 of 92

Last Updated: 09/26/2026